$AZTA News

Winners And Losers Of Q1: Azenta (NASDAQ:AZTA) Vs The Rest Of The Drug Development Inputs & Services Stocks

Azenta Publishes 2025 Environmental, Social, and Governance (ESG) Report

Azenta’s Q1 Earnings Call: Our Top 5 Analyst Questions

Azenta, Inc. Q2 2026 Earnings Call Summary

Needham Maintains Buy on Azenta, Lowers Price Target to $33

Azenta Q2 Earnings Call Highlights

Azenta, Inc. (AZTA) Q2 2026 Earnings Call Transcript

Azenta, Inc. 2026 Q2 - Results - Earnings Call Presentation

Azenta Reports Second Quarter Results for Fiscal 2026, Ended March 31, 2026, Updates Full Year Fiscal 2026 Guidance, and Extends Long-Range Plan to 2029

Azenta Sees FY2026 Sales $603.000M-$621.000M vs $623.837M Est

Azenta Q2 Adj. EPS $0.08 Misses $0.12 Estimate, Sales $145.000M Miss $148.740M Estimate

Assessing Azenta (AZTA) Valuation After Recent Share Price Volatility

Evercore Cuts Azenta (AZTA) Price Target, Keeps Outperform Rating

Azenta Announces Fiscal 2026 Second Quarter Conference Call and Webcast

Azenta (AZTA) Fell on Operational Challenges and Uneven Execution

Azenta (AZTA) Stock Drops 13% After-Hours — What's Happening?

Assessing Azenta (AZTA) Valuation After A Short-Term Rebound And Longer-Term Share Price Weakness

Azenta Life Sciences Announces Leadership Transition to Accelerate Gene Synthesis Strategy and Multiomics Execution

Evercore ISI Group Maintains Outperform on Azenta, Lowers Price Target to $35

Azenta: Life Science Player Fails To Come To Life